These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33933425)

  • 41. Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach.
    Joseph G; Kaplan C; Luce J; Lee R; Stewart S; Guerra C; Pasick R
    Public Health Genomics; 2012; 15(3-4):172-80. PubMed ID: 22488460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.
    Nair N; Bellcross C; Haddad L; Martin M; Matthews R; Gabram-Mendola S; Crane B; Meaney-Delman D
    J Cancer Educ; 2017 Mar; 32(1):119-124. PubMed ID: 26637472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Genetic Counseling of HBOC and Japanese Organization of HBOC].
    Fukushima Y
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):107-110. PubMed ID: 28223668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beyond BRCA1 and BRCA2.
    King-Spohn K; Pilarski R
    Curr Probl Cancer; 2014; 38(6):235-48. PubMed ID: 25497410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool.
    Rupert DJ; Squiers LB; Renaud JM; Whitehead NS; Osborn RJ; Furberg RD; Squire CM; Tzeng JP
    Patient Educ Couns; 2013 Aug; 92(2):188-96. PubMed ID: 23664232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    Garcia C; Sullivan MW; Lothamer H; Harrison KM; Chatfield L; Thomas MH; Modesitt SC
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1835-1841. PubMed ID: 32656916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
    De Simone LM; Arjunan A; Vogel Postula KJ; Maga T; Bucheit LA
    J Genet Couns; 2021 Feb; 30(1):158-169. PubMed ID: 32562467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population-based genetic testing for Women's cancer prevention.
    Evans O; Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.
    Levy DE; Garber JE; Shields AE
    J Gen Intern Med; 2009 Jul; 24(7):822-8. PubMed ID: 19455369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
    Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
    J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
    Petelin L; James PA; Trainer AH
    Intern Med J; 2018 Oct; 48(10):1269-1272. PubMed ID: 30288903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
    Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
    J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
    Shao D; Cheng S; Guo F; Zhu C; Yuan Y; Hu K; Wang Z; Meng X; Jin X; Xiong Y; Chai X; Li H; Zhang Y; Zhang H; Liu J; Ye M
    Cancer Sci; 2020 Feb; 111(2):647-657. PubMed ID: 31742824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families.
    Berzina D; Nakazawa-Miklasevica M; Zestkova J; Aksenoka K; Irmejs A; Gardovskis A; Kalniete D; Gardovskis J; Miklasevics E
    BMC Med Genet; 2013 Jun; 14():61. PubMed ID: 23767878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
    Nippert I; Schlegelberger B;
    Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.